[go: up one dir, main page]

HRP20191942T1 - Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije - Google Patents

Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije Download PDF

Info

Publication number
HRP20191942T1
HRP20191942T1 HRP20191942TT HRP20191942T HRP20191942T1 HR P20191942 T1 HRP20191942 T1 HR P20191942T1 HR P20191942T T HRP20191942T T HR P20191942TT HR P20191942 T HRP20191942 T HR P20191942T HR P20191942 T1 HRP20191942 T1 HR P20191942T1
Authority
HR
Croatia
Prior art keywords
purin
amino
methyl
propylsulfonimidoyl
oxo
Prior art date
Application number
HRP20191942TT
Other languages
English (en)
Inventor
Chungen Liang
Kun MIAO
Jianping Wang
Hongying Yun
Xiufang ZHENG
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20191942T1 publication Critical patent/HRP20191942T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

1. Spoj, naznačen time, da je predstavljen formulom (I), u kojoj R1 je C1−6alkil, halogenC1−6alkil, C3−7cilkoalkilC1−6alkil, C1−6alkoksiC1−6alkil ili pirolidinilC1−6alkil; R2 je C1−6alkil, fenilC1−6alkil, piridinilC1−6alkil ili pirimidinilC1−6alkil, gdje su spomenuti fenilC1−6alkil, piridinilC1−6alkil i pirimidinilC1−6alkil nesupstituirani ili supstituirani s jednim, dva ili tri supstituenta, neovisno odabrana iz sljedeće skupine: halogen, C1−6alkil, C1−6alkoksi, cijano, karboksi, karbamoil, haloC1−6alkil, C1−6alkilsulfonil, C1−6alkoksikarbonil, C1−6alkoksiC1−6alkilaminokarbonil, pirolidinilkarbonil i piperidinilkarbonil; R3 je H; ili njegova farmaceutski prihvatljiva sol, njegov enantiomer ili dijastereomer.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da R1 je metil, etil, propil, butil, kloropropil, cikloheksilmetil, metoksietil, metoksipropil, pirolidinilpropil ili trifluoroetil; R2 je izobutil, benzil, klorobenzil, fluorobenzil, bromobenzil, klorofluorobenzil, klorometilbenzil, diklorobenzil, difluorobenzil, metilbenzil, metoksibenzil, cijanobenzil, karbamoilbenzil, trifluorometilbenzil, metilsulfonilbenzil, metoksikarbonilbenzil, karboksibenzil, metoksietilaminokarbonilbenzil, piperidinilkarbonilbenzil, pirolidinilkarbonilbenzil, piridinilmetil, kloropiridinilmetil, metilpiridinilmetil, pirimidinilmetil ili metilpirimidinilmetil; R3 je H; ili njegova farmaceutski prihvatljiva sol, njegov enantiomer ili dijastereomer.
3. Spoj prema patentnom zahtjevu 1, naznačen time, da R1 je C1−6alkil, halogenC1−6alkil ili C1−6alkoksiC1−6alkil.
4. Spoj prema patentnom zahtjevu 3, naznačen time, da R1 je metil, etil, propil, butil, kloropropil, trifluoroetil, metoksietil ili metoksipropil.
5. Spoj prema patentnom zahtjevu 3, naznačen time, da R1 je C1−6alkil.
6. Spoj prema patentnom zahtjevu 2 ili 5, naznačen time, da R1 je metil, etil ili propil.
7. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je odabran iz skupine koju čine: 6-Amino-9-benzil-2-(metilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-benzil-2-(etilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-benzil-2-(2-metoksietilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-benzil-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-benzil-2-(butilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-benzil-2-(3-metoksipropilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-benzil-2-(2,2,2-trifluoroetilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-benzil-2-(cikloksiheksilmetilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-klorofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-metoksifenil)metil]-2-(metilsulfonimidoil)-7H-purin-8-on; 6-Amino-2-(3-kloropropilsulfonimidoil)-9-[(4-metoksifenil)metil]-7H-purin-8-on; 6-Amino-9-[(4-metoksifenil)metil]-2-(3-pirolidin-1-ilpropilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-klorofenil)metil]-2-(metilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(6-kloro-3-piridil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(2-klorofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-2-(metilsulfonimidoil)-9-(3-piridilmetil)-7H-purin-8-on; 3-[[6-Amino-8-okso-2-(propilsulfonimidoil)-7H-purin-9-il]metil]benzonitril; 3-[[6-Amino-8-okso-2-(propilsulfonimidoil)-7H-purin-9-il]metil]benzamid; 6-Amino-2-(metilsulfonimidoil)-9-(2-piridilmetil)-7H-purin-8-on; 6-Amino-2-(metilsulfonimidoil)-9-(4-piridilmetil)-7H-purin-8-on; 6-Amino-9-izobutil-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(3-klorofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-2-(propilsulfonimidoil)-9-[[4-(trifluorometil)fenil]metil]-7H-purin-8-on; 6-Amino-9-[(4-fluorofenil)metil]]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-bromofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(3,4-diklorofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-(3,4-difluorofenilmetil)-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-kloro-3-metil-fenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-2-(propilsulfonimidoil)-9-(p-tolilmetil)-7H-purin-8-on; 6-Amino-9-[(4-kloro-3-fluorofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(2,4-difluorofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 4-[[6-Amino-8-okso-2-(propilsulfonimidoil)-7H-purin-9-il]metil]benzonitril; 4-[[6-Amino-8-okso-2-(propilsulfonimidoil)-7H-purin-9-il]metil]benzamid; 6-Amino-9-[(6-metil-3-piridil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(2-metil-4-piridil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(3-kloro-4-metil-fenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-metilsulfonilfenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; Metil 4-[[6-amino-8-okso-2-(propilsulfonimidoil)-7H-purin-9-il]metil]benzoat; 4-[[6-Amino-8-okso-2-(propilsulfonimidoil)-7H-purin-9-il]metil]benzojeva kiselina; 4-[[6-Amino-8-okso-2-(propilsulfonimidoil)-7H-purin-9-il]metil]-N-(2-metoksietil)benzamid; 6-Amino-9-[[4-(piperidin-1-karbonil)fenil]metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-2-(S-propilsulfonimidoil)-9-[[4-(pirolidin-1-karbonil)fenil]metil]-7H-purin-8-on; 6-Metil-2-(propilsulfonimidoil)-9-(pirimidin-5-ilmetil)-7-purin-8-on; 6-Metil-9-[(2-metilpirimidin-5-il)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-klorofenil)metil]-2-(etilsulfonimidoil)-7H-purin-8-on; 6-Amino-2-(etilsulfonimidoil)-9-(p-tolilmetil)-7H-purin-8-on; i 6-Amino-2-(etilsulfonimidoil)-9-[(4-fluorofenil)metil]-7H-purin-8-on.
8. Spoj prema bilo kojem od patentnih zahtjeva 1, 2 ili 7, naznačen time, da je odabran iz skupine koju čine: 6-Amino-9-benzil-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-klorofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(6-kloro-3-piridil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-fluorofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-bromofenil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-2-(propilsulfonimidoil)-9-(p-tolilmetil)-7H-purin-8-on; 6-Amino-9-[(6-metil-3-piridil)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; Metil 4-[[6-amino-8-okso-2-(propilsulfonimidoil)-7H-purin-9-il]metil]benzoat; 4-[[6-Amino-8-okso-2-(propilsulfonimidoil)-7H-purin-9-il]metil]benzojeva kiselina; 6-Metil-9-[(2-metilpirimidin-5-il)metil]-2-(propilsulfonimidoil)-7H-purin-8-on; 6-Amino-9-[(4-klorofenil)metil]-2-(etilsulfonimidoil)-7H-purin-8-on; i 6-Amino-2-(etilsulfonimidoil)-9-(p-tolilmetil)-7H-purin-8-on.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da je odabran iz skupine koju čine: 6-Amino-9-[(4-klorofenil)metil]-2-(etilsulfonimidoil)-7H-purin-8-on; i 6-Amino-2-(etilsulfonimidoil)-9-(p-tolilmetil)-7H-purin-8-on.
10. Spoj, naznačen time, da je predstavljen formulom (Ia), u kojoj R4 je C1−6alkil, halogenC1−6alkil, C3−7cilkoalkilC1−6alkil, C1−6alkoksiC1−6alkil ili pirolidinilC1−6 alkil; R5 je C1−6alkil, fenilC1−6alkil, piridinilC1−6alkil ili pirimidinilC1−6alkil, gdje su spomenuti fenilC1−6alkil, piridinilC1−6alkil i pirimidinilC1−6alkil nesupstituirani ili supstituirani s jednim, dva ili tri supstituenta, neovisno odabrana iz skupine koju čine sljedeći: halogen, C1−6alkil, C1−6alkoksi, cijano, karboksi, karbamoil, haloC1−6alkil, C1−6alkilsulfonil, C1−6alkoksikarbonil, C1−6alkoksiC1−6alkilaminokarbonil, pirolidinilkarbonil i piperidinilkarbonil; R6 je H ili C1−6alkil-C(O)O-C1−6alkil−; R7 je H, C1−6alkil, C3−7cikloalkil ili C1−10alkilkarbonil; R8 je H, C1−6alkilkarbonil, karboksiC1−6alkilkarbonil, C1−6alkioksikarbonilC1−6alkilkarbonil ili benzoil; pod uvjetom da R6, R7 i R8 nisu H istodobno; ili njegova farmaceutski prihvatljiva sol, njegov enantiomer ili dijastereomer.
11. Spoj prema patentnom zahtjevu 10, naznačen time, da je odabran iz skupine koju čine: N-[(6-Amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]pentanamid; N-[[6-Amino-9-[(4-klorofenil)metil]-8-okso-7H-purin-2-il]-okso-propil-λ4-sulfaniliden]acetamid; N-[(6-Amino-9-benzil-8-okso-7H-purin-2-il)-metil-okso-λ4-sulfaniliden]acetamid; 4-[[(6-Amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]amino]-4-okso-butanoična kiselina; 4-[[(6-Amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]amino]-4-okso-butanoična kiselina; 4-[[(6-Amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]amino]-4-okso-butanoična kiselina; Etil 4-[[(6-amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]amino]-3-okso-butanoat; Etil 4-[[(6-amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]amino]-4-okso-butanoat; Etil 4-[[(6-amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]amino]-4-okso-butanoat; N-[(6-Amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]benzamid; N-[(6-Amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]benzamid; N-[(6-Amino-9-benzil-8-okso-7H-purin-2-il)-okso-propil-λ4-sulfaniliden]benzamid; 9-Benzil-6-(etilamino)-2-(propilsulfonimidoil)-7H-purin-8-on; 6-(Etilamino)-9-[(6-metil-3-piridil)metil]-2(S-propilsulfonimidoil)-7H-purin-8-on; 9-[(4-Klorofenil)metil]-6-(etilamino)-2-(propilsulfonimidoil)-7H-purin-8-on; 9-Benzil-6-(propilamino)-2-(propilsulfonimidoil)-7H-purin-8-on; 9-Benzil-6-(izopropilamino)-2-(propilsulfonimidoil)-7H-purin-8-on; 9-Benzil-6-(ciklopropilamino)-2-(propilsulfonimidoil)-7H-purin-8-on; N-[9-[(4-Klorofenil)metil]-8-okso-2-(propilsulfonimidoil)-7H-purin-6-il]-2-propil-pentanamid; N-[9-[(4-Klorofenil)metil]-8-okso-2-(propilsulfonimidoil)-7H-purin-6-il]acetamid; N-[9-Benzil-8-okso-2-(propilsulfonimidoil)-7H-purin-6-il]pentanamid; N-[9-[(4-Klorofenil)metil]-8-okso-2-(propilsulfonimidoil)-7H-purin-6-il]-2-etil-butanamid; N-[9-[(4-Klorofenil)metil]-8-okso-2-(propilsulfonimidoil)-7H-purin-6-il]-3-metil-butanamid; N-[9-[(4-Klorofenil)metil]-8-okso-2-(propilsulfonimidoil)-7H-purin-6-il]-2-metil-pentanamid; N-[9-[(4-Klorofenil)metil]-8-okso-2-(propisulfonimidoil)-7H-purin-6-il]-2,2-dimetil-propanamid; N-[9-Benzil-8-okso-2-(propilsulfonimidoil)-7H-purin-6-il]-2-propil-pentanamid; [6-Amino-9-benzil-2-(metilsulfonimidoil)-8-okso-purin-7-il]metil-acetat; [6-Amino-9-benzil-8-okso-2-(propilsulfonimidoil)purin-7-il]metil-acetat; [6-Amino-9-benzil-8-okso-2-(propilsulfonimidoil)purin-7-il]metil-2,2-dimetilpropanoat; i 1-[6-Amino-9-benzil-8-okso-2-(propilsulfonimidoil)purin-7-il]etil-acetat.
12. Postupak za pripremu spoja prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da sadrži sljedeće korake: (a) reakciju spoja formule (IIa), s reagensom za iminaciju; (b) reakciju spoja formule (IIb), s reagensom za iminaciju; pri čemu Ra je R1 ili R4, Rb je R2 ili R5, R7 je C1−6alkil ili C3−7cikloalkil; (c) reakciju spoja formule (IIIc), s oksidansom nakon čega slijedi iminacijski reagens, pri čemu Ra je R1 ili R4, Rb je R2 ili R5, R12 je C1−10alkil; (d) reakciju spoja formule (IIIa), s oksidansom nakon čega slijedi iminacijski reagens, pri čemu Ra je R1 ili R4, Rb je R2 ili R5; (e) reakciju spoja formule (Ie), s haloesterom; (f) reakciju spoja formule (Ie), s karboksilnim anhidridom ili acil-kloridom; gdje su R1, R2, R4 i R5 isti kao što su definirani u bilo kojem od patentnih zahtjeva 1 do 29.
13. Spoj ili farmaceutski prihvatljiva sol, enantiomer ili dijastereomer prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da se upotrebljava kao terapijski djelatna tvar.
14. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 11 i terapijski inertni nosač.
15. Spoj ili farmaceutski prihvatljiva sol, enantiomer ili dijastereomer prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da se upotrebljava u liječenju ili profilaksi infekcije virusom hepatitisa B.
HRP20191942TT 2015-05-08 2019-10-24 Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije HRP20191942T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
EP16720421.3A EP3294740B1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
HRP20191942T1 true HRP20191942T1 (hr) 2020-01-10

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191942TT HRP20191942T1 (hr) 2015-05-08 2019-10-24 Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije

Country Status (33)

Country Link
US (3) US9708325B2 (hr)
EP (1) EP3294740B1 (hr)
JP (1) JP6738352B2 (hr)
KR (1) KR102690131B1 (hr)
CN (1) CN107580596B (hr)
AR (1) AR104528A1 (hr)
AU (3) AU2016260683B2 (hr)
BR (1) BR112017023959B1 (hr)
CA (1) CA2982704C (hr)
CL (1) CL2017002745A1 (hr)
CO (1) CO2017009994A2 (hr)
CR (1) CR20170496A (hr)
DK (1) DK3294740T3 (hr)
ES (1) ES2753777T3 (hr)
HK (1) HK1247925A1 (hr)
HR (1) HRP20191942T1 (hr)
HU (1) HUE045906T2 (hr)
IL (2) IL254947B (hr)
LT (1) LT3294740T (hr)
MX (2) MX376761B (hr)
MY (1) MY182353A (hr)
NZ (2) NZ775222A (hr)
PE (1) PE20171620A1 (hr)
PH (1) PH12017502009A1 (hr)
PL (1) PL3294740T3 (hr)
PT (1) PT3294740T (hr)
RS (1) RS59435B1 (hr)
RU (1) RU2745269C2 (hr)
SG (1) SG10202108841YA (hr)
SI (1) SI3294740T1 (hr)
TW (2) TWI768467B (hr)
UA (1) UA120450C2 (hr)
WO (1) WO2016180695A1 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ775222A (en) 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2019002129A (es) * 2016-08-29 2019-06-20 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
CA3034185A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
BR112020016509A2 (pt) * 2018-02-28 2020-12-15 F. Hoffmann-La Roche Ag Composto, composto para uso no tratamento ou profilaxia do câncer de fígado, composição farmacêutica ou medicamento, uso e método para o tratamento ou profilaxia do câncer de fígado
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
US20220226488A1 (en) * 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
CN114450280B (zh) 2019-09-20 2025-02-25 先正达农作物保护股份公司 具有含硫和亚砜亚胺取代基的杀有害生物活性杂环衍生物
CN119604517A (zh) 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
AP2011005745A0 (en) * 2008-12-09 2011-06-30 Gilead Sciences Inc Modulators of toll-like receptors.
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TW201636330A (zh) * 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
AU2012334127B2 (en) 2011-11-09 2017-05-18 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
JP6336036B2 (ja) 2013-03-29 2018-06-06 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療のための大環状デアザプリノン
PT3190113T (pt) 2014-08-15 2021-06-17 Chai Tai Tianqing Pharmaceutical Group Co Ltd Compostos pirrolopirimidina utilizados como agonistas de tlr7
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2019002129A (es) * 2016-08-29 2019-06-20 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.

Also Published As

Publication number Publication date
AU2020256348B2 (en) 2022-06-16
US20160326177A1 (en) 2016-11-10
CL2017002745A1 (es) 2018-05-18
ES2753777T3 (es) 2020-04-14
TW201716410A (zh) 2017-05-16
BR112017023959B1 (pt) 2023-05-02
SI3294740T1 (sl) 2019-12-31
UA120450C2 (uk) 2019-12-10
HK1247925A1 (zh) 2018-10-05
AU2022204666A1 (en) 2022-07-21
CR20170496A (es) 2017-12-05
CN107580596A (zh) 2018-01-12
IL280769B1 (en) 2023-03-01
NZ775222A (en) 2024-09-27
CA2982704A1 (en) 2016-11-17
HUE045906T2 (hu) 2020-01-28
IL254947A0 (en) 2017-12-31
RU2017142577A (ru) 2019-06-10
PT3294740T (pt) 2019-10-29
US20170275286A1 (en) 2017-09-28
JP2018515509A (ja) 2018-06-14
SG10202108841YA (en) 2021-09-29
MX2017014033A (es) 2018-03-01
JP6738352B2 (ja) 2020-08-12
LT3294740T (lt) 2019-11-25
US20200109144A1 (en) 2020-04-09
US11242345B2 (en) 2022-02-08
RS59435B1 (sr) 2019-11-29
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
IL280769A (en) 2021-04-29
TWI706954B (zh) 2020-10-11
IL280769B2 (en) 2023-07-01
US10399983B2 (en) 2019-09-03
KR102690131B1 (ko) 2024-07-31
NZ735648A (en) 2023-06-30
PH12017502009A1 (en) 2018-03-26
EP3294740A1 (en) 2018-03-21
AU2016260683A1 (en) 2017-10-12
TWI768467B (zh) 2022-06-21
CO2017009994A2 (es) 2018-02-20
US9708325B2 (en) 2017-07-18
IL254947B (en) 2021-02-28
CA2982704C (en) 2023-10-24
PL3294740T3 (pl) 2020-03-31
MY182353A (en) 2021-01-20
PE20171620A1 (es) 2017-11-02
WO2016180695A1 (en) 2016-11-17
AU2016260683B2 (en) 2020-10-29
EP3294740B1 (en) 2019-09-04
KR20180003612A (ko) 2018-01-09
RU2017142577A3 (hr) 2019-10-31
MX376761B (es) 2025-03-07
AR104528A1 (es) 2017-07-26
MX2020010949A (es) 2022-06-16
BR112017023959A2 (pt) 2018-07-17
CN107580596B (zh) 2020-07-14
AU2020256348A1 (en) 2020-11-12
DK3294740T3 (da) 2019-11-04

Similar Documents

Publication Publication Date Title
HRP20191942T1 (hr) Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije
JP2018515509A5 (hr)
ES2453591T3 (es) Derivado de uracilo o timina para el tratamiento de la hepatitis C
RU2018123779A (ru) Новые соединения
HRP20161177T1 (hr) Modulator glukagonskog receptora
SI2970155T1 (en) INHIBITORS INDOLEAMIN 2,3-DIOXYGENESIS (IDO)
HRP20150704T1 (hr) Derivati piperidinona kao mdm2-inhibitori za lijeäśenje raka
JP2017537949A5 (hr)
JP2013531074A5 (hr)
JP2016503779A5 (hr)
IL229395A0 (en) Modified release of4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids
JP2015514056A5 (hr)
JP2016506962A5 (hr)
HRP20240161T1 (hr) Inhibitor atr i njegova primjena
JP2009538897A5 (hr)
RS50236B (sr) Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
JP2011515398A5 (hr)
RU2006106272A (ru) Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae
ME00427B (me) N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze
JP2015529235A5 (hr)
JP2012509263A5 (hr)
JP2018518522A5 (hr)
JP2018048143A5 (hr)
RU2016150518A (ru) Алкильные производные 1-окса-4,9-диазаспироундекановых соединений, обладающих мультимодальной активностью, направленной против боли